World Journal of Pharmaceutical and Medical Research (WJPMR) has indexed with various reputed international bodies like : Google Scholar , Index Copernicus , SOCOLAR, China , Indian Science Publications , Cosmos Impact Factor , Research Bible, Fuchu, Tokyo. JAPAN , Scientific Indexing Services (SIS) , UDLedge Science Citation Index , International Impact Factor Services , International Society for Research Activity (ISRA) Journal Impact Factor (JIF) , International Innovative Journal Impact Factor (IIJIF) , Scientific Journal Impact Factor (SJIF) , Global Impact Factor (In Process) , Digital Online Identifier-Database System (DOI-DS) , Science Library Index, Dubai, United Arab Emirates , Eurasian Scientific Journal Index (ESJI) , International Scientific Indexing, (ISI) UAE , IFSIJ Measure of Journal Quality , Web of Science Group (Under Process) , Directory of Research Journals Indexing , 

World Journal of Pharmaceutical
and Medical Research

An International Peer Reviewed Journal for Pharmaceutical and Medical Research and Technology
An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)
ISSN 2455-3301
IMPACT FACTOR: 5.922

ICV : 78.6

Abstract

SOME INDICATORS OF PHARMACOKINETICS OF SODIUM DICLOFENAC IN PATIENTS WITH RHEUMATOID ARTHRITIS TAKING INTO ACCOUNT COMORBIDE CONDITIONS

N. X. Tukhtaeva*, M. Sh. Karimov and G. X. Khasanova

ABSTRACT

The aim of the study was to study in a comparative aspect some of the pharmacokinetics of Diclofenac sodium in patients with rheumatoid arthritis with impaired gastric microbiocenosis (gastric dysbiosis) and without disturbance (without dysbiosis). Material and methods: We examined 38 patients aged 18 to 60 years, with I-II-III degree of disease activity. In addition to general clinical examination conductedenzyme immunoassay and urease test to determine Helicobacter pylori andhigh performance liquid chromatography to determine the pharmacokinetics of diclofenac. Results: studies and analysis of their results indicate that in conditions of rheumatoid arthritis, in particular, in the presence of comorbid conditions, there is a decrease in the metabolic rate and lengthening the half-life of NSAIDs, which increases the risk of side effects, especially from the gastrointestinal tract and significantly affects the course of the disease and treatment results.

[Full Text Article]

Powered By WJPMR | All Right Reserved

WJPMR